SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001193125-24-093305
Filing Date
2024-04-11
Accepted
2024-04-11 16:39:14
Documents
21
Period of Report
2024-06-05

Document Format Files

Seq Description Document Type Size
1 PRE 14A d75541dpre14a.htm   iXBRL PRE 14A 685362
6 GRAPHIC g75541dsp028.jpg GRAPHIC 208533
7 GRAPHIC g75541dsp029.jpg GRAPHIC 249942
8 GRAPHIC g75541dsp030.jpg GRAPHIC 228811
9 GRAPHIC g75541g02s02.jpg GRAPHIC 33489
10 GRAPHIC g75541g35g35.jpg GRAPHIC 110253
11 GRAPHIC g75541g36g36.jpg GRAPHIC 117703
  Complete submission text file 0001193125-24-093305.txt   3964733

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20231231.xsd EX-101.SCH 6005
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20231231_def.xml EX-101.DEF 6721
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20231231_lab.xml EX-101.LAB 9604
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20231231_pre.xml EX-101.PRE 5979
24 EXTRACTED XBRL INSTANCE DOCUMENT d75541dpre14a_htm.xml XML 222983
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38890 | Film No.: 24838982
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)